Aleph-4

From Wikipedia, the free encyclopedia
(Redirected from ALEPH-4)
Jump to navigation Jump to search
Aleph-4
File:Aleph-4 v2.svg
Clinical data
Other namesALEPH-4; DOT-4; 4-Isopropylthio-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-isopropylthioamphetamine; 4-iPrS-DMA
Routes of
administration
Oral[1]
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action12–20 hours[1]
Identifiers
  • 1-(2,5-dimethoxy-4-propan-2-ylsulfanylphenyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC14H23NO2S
Molar mass269.40 g·mol−1
3D model (JSmol)
  • CC(C)SC1=C(C=C(C(=C1)OC)CC(C)N)OC
  • InChI=1S/C14H23NO2S/c1-9(2)18-14-8-12(16-4)11(6-10(3)15)7-13(14)17-5/h7-10H,6,15H2,1-5H3
  • Key:BCWCXWKCQMBFBQ-UHFFFAOYSA-N

Aleph-4, or ALEPH-4, also known as 4-isopropylthio-2,5-dimethoxyamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families.[1] It is one of the Aleph series of compounds.[1] In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists Aleph-4's dose as 7 to 12 mg orally and its duration as 12 to 20 hours.[1] The effects of Aleph-4 have been reported to include closed-eye imagery, enhanced visual appreciation, emotional changes, and physical side effects and toxicity indications, among others.[1] One of the reports remarked that it was "one of the most profound and deep learning experiences" they had had.[1] However, Shulgin was unwilling to push the dose higher than 12 mg due to toxicity concerns.[1] The chemical synthesis of Aleph-4 has been described.[1] Aleph-4 was first described in the scientific literature by Shulgin, David E. Nichols, Peyton Jacob III, and other colleagues in 1978.[2] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991.[1] The drug was encountered as a novel designer drug in Japan in 2009.[3][4]

See also

[edit | edit source]

References

[edit | edit source]
  1. ^ a b c d e f g h i j Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).https://erowid.org/library/books_online/pihkal/pihkal005.shtml
  2. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  3. ^ Suzuki, J., Moriyasu, T., Nagashima, M., Kanai, C., Shimizu, M., Hamano, T., & Nagayama, T. (2010). Analysis of uncontrolled drugs purchased in fiscal year 2009. Ann RepTokyo Metrop Inst Public Health [Japanese: Tōkyō-to Kenkō Anzen Kenkyū Sentā Kenkyū Nenpō], 61, 163–172. https://isomerdesign.com/bitnest/external/TokyoMetr.Inst.PH/61.163
  4. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
[edit | edit source]